No survival benefit from aspirin in COVID-19 patients
The NIHR-supported RECOVERY trial found that the anti-inflammatory drug does not improve survival for hospitalised patients with COVID-19
Read More
Tag: aspirin
UK study will evaluate aspirin as a potential COVID-19 treatment
RECOVERY study will assess if drug can reduce risk of blood clots
Read More
US priority review for AZ’ Brilinta/aspirin combination
Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke
Read More
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More
Bayer files low-dose Xarelto/aspirin combo
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Read More
Trial finds higher aspirin bleed risk for elderly
The use of daily aspirin as a blood thinner in people aged over 75 years is linked with a much higher risk of major and potentially fatal stomach bleeds than previously thought.
Read More
GPs want more support in prescribing cancer prevention drugs
GPs need better support in prescribing medicines that lower the risk of certain cancers, according to a new study by Cancer Research UK, published in the British Journal of General Practice.
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
